Patients with triple-negative breast cancer (TNBC) have been shown to have a substantially shortened median survival when compared to patients with hormone receptor positive (HR+, HER2−) and HER2+ breast cancer [4, 5]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.